Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Investment Securities (2019 - 2025)

BridgeBio Pharma's Gains from Investment Securities history spans 7 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 68.37% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.6 million, down 77.62%, while the annual FY2024 figure was $12.5 million, 922.95% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $1.3 million at BridgeBio Pharma, down from $1.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.5 million in Q3 2023 and bottomed at -$5.2 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $144187.0 (2023), against an average of $686797.1.
  • The largest annual shift saw Gains from Investment Securities tumbled 1021.47% in 2023 before it surged 2554.96% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $4.3 million in 2021, then plummeted by 88.59% to $489000.0 in 2022, then crashed by 1021.47% to -$4.5 million in 2023, then fell by 15.11% to -$5.2 million in 2024, then surged by 125.68% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Gains from Investment Securities are $1.3 million (Q3 2025), $1.5 million (Q2 2025), and $4.0 million (Q1 2025).